Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake
Ticker: PRCWF · Form: SC 13D/A · Filed: Jul 29, 2024 · CIK: 1863362
| Field | Detail |
|---|---|
| Company | Procaps Group, S.A. (PRCWF) |
| Form Type | SC 13D/A |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, schedule-13d
TL;DR
Hoche Partners Pharma Holding S.A. updated its 13D filing for Procaps Group, S.A. on 7/29/24.
AI Summary
Hoche Partners Pharma Holding S.A. filed an amendment (No. 4) to its Schedule 13D on July 29, 2024, regarding its holdings in Procaps Group, S.A. The filing indicates a change in the reporting person's beneficial ownership of the ordinary shares of Procaps Group, S.A.
Why It Matters
This amendment signals a potential shift in the ownership structure or strategy of Procaps Group, S.A., which could impact its stock price and future business decisions.
Risk Assessment
Risk Level: medium — Changes in major shareholder filings can indicate shifts in control or strategy, potentially affecting stock price volatility.
Key Players & Entities
- Hoche Partners Pharma Holding S.A. (company) — Reporting person filing amendment
- Procaps Group, S.A. (company) — Subject company
- July 29, 2024 (date) — Date of event requiring filing
FAQ
What specific changes are detailed in Amendment No. 4 to the Schedule 13D filing?
The filing is an amendment (No. 4) to the Schedule 13D, indicating a change in the reporting person's beneficial ownership of Procaps Group, S.A. ordinary shares. Specific details of the change are not provided in the header information.
Who is the reporting person in this filing?
The reporting person is Hoche Partners Pharma Holding S.A.
What is the subject company of this filing?
The subject company is Procaps Group, S.A.
When was this amendment filed?
This amendment was filed on July 29, 2024.
What is the CUSIP number for the ordinary shares of Procaps Group, S.A. mentioned in the filing?
The CUSIP number for the ordinary shares of Procaps Group, S.A. is L7756P 102.
Filing Stats: 867 words · 3 min read · ~3 pages · Grade level 8.9 · Accepted 2024-07-29 15:26:01
Key Financial Figures
- $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securiti
Filing Documents
- procaps_13da4.htm (SC 13D/A) — 38KB
- ex99_15.htm (EX-99.15) — 21KB
- ex99_15.jpg (GRAPHIC) — 3KB
- 0001019056-24-000215.txt ( ) — 65KB
Purpose
Item 4. Purpose of the Transaction Item 4 of the Schedule 13D is amended and supplemented as follows: On July 25, 2024, the Reporting Person made a non-binding bona fide financing offer to the Board of Directors (the “ Board ”) of the Issuer that remained open until 5 p.m. on July 28, 2024. The majority shareholder did not accept certain conditions related to the reconstitution of the Board that were included in the offer. Currently, the Reporting Person considers its offer rejected. On July 29, 2024, legal counsel to the Reporting Person issued a letter to the Chief Executive Officer and members of the Board of the Issuer. The letter is attached hereto as Exhibit 99.15.
Materials to be Filed as Exhibits
Item 7. Materials to be Filed as Exhibits. Item 7 of the Schedule 13D is hereby amended by adding the following: Exhibit 99.15 — Letter from Gibbons P.C. to the Chief Executive Officer and Board of Directors of Procaps Group, S.A. dated July 29, 2024. SIGNATURE After reasonable inquiry and to the best of the Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: July 29, 2024 hoche partners pharma holding s.a. By: /s/ Roman Sokolowski Name: Roman Sokolowski Title: Director Stonehage Fleming Corporate Service Luxembourg S.A., Director By: /s/ Alexander Ludbrook - Miles Name: Alexander Ludbrook - Miles Title: Director By: /s/ Ariane Vansimpsen Name: Ariane Vansimpsen Title: Director